AbbVie Inc outlook FY adjusted EPS USD 13.87 - 14.07
ABBV•AbbVie reports second-quarter results and updated guidance
Jul 31 (Reuters) - AbbVie Inc Q2 Global Skyrizi revenue USD 5,505 million.
- Q2 Global Rinvoq revenue USD 2,525 million
- Q2 EPS USD 2.03
- Q2 revenue USD 16,990 million vs. IBES estimate USD 16,765 million
- Q2 Global Humira revenue USD 756 million
- Q2 Adjusted EPS USD 3.65 vs. IBES estimate USD 3.6
- Q2 results include an unfavorable impact of $0.17/share related to acquired IPR&D and milestones expense
- FY 2026 adj EPS guidance includes $0.14/share dilutive impact related to acquisition of Apogee Therapeutics
